Dabrafenib N-Oxide Impurity 3 - Request Quote
Dabrafenib N-Oxide Impurity 3
| SZ CAT No: | SZ-D120043 |
| CAS No | NA |
| Mol.F. | C23H20F3N5O3S2 |
| Mol.Wt. | 535.6 |
| Inv. Status | Synthesis on demand |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Dabrafenib N-Oxide Impurity 3 is chemically 2-Amino-6-(2-(tert-butyl)-4-(3-((2,6-difluorophenyl)sulfonamido)-2-fluorophenyl)thiazol-5-yl)pyrimidine 1-oxide. Dabrafenib N-Oxide Impurity 3 is supplied with detailed characterization data compliant with regulatory guideline. Dabrafenib N-Oxide Impurity 3 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Dabrafenib.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
buy high quality Dabrafenib N-Oxide Impurity 3
Purchase Dabrafenib N-Oxide Impurity 3
Dabrafenib N-Oxide Impurity 3 suppliers
Dabrafenib N-Oxide Impurity 3 manufacturers
Dabrafenib N-Oxide Impurity 3 price
Order Dabrafenib N-Oxide Impurity 3
Enquire Dabrafenib N-Oxide Impurity 3
Dabrafenib N-Oxide Impurity 3 cost
Dabrafenib N-Oxide Impurity 3 Supplier
Dabrafenib N-Oxide Impurity 3 Distributor
Dabrafenib N-Oxide Impurity 3 for Method Validation
Dabrafenib Reference Standard
Dabrafenib N-Oxide Impurity 3 for ANDA Filing
Dabrafenib N-Oxide Impurity 3 for Forced Degradation Studies
Dabrafenib N-Oxide Impurity 3 Identification Standards
Dabrafenib N-Oxide Impurity 3 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.